Qvanteq AG chosen as a 2015 Red Herring Europe Winner

Amsterdam, Netherlands – Red Herring announced its Red Herring Europe award winners today, recognizing Europe’s leading private companies and celebrating these startups’ innovations and technologies across their respective industries. Red Herring’s Top 100 Europe list has become a mark of distinction for identifying promising new companies and entrepreneurs. Red Herring’s editors were among the first […]

First patient enrolled in the QUEST I clinical study

Qvanteq AG today announced that it has enrolled the first patient in the First in Man (FiM) clinical study QUEST I, this is following earlier regulatory approval from the Dutch and Swiss authorities. The aim of the QUEST I study is to assess feasibility and safety of the Qstent, a bioactive, coating-free coronary stent. The […]

The Swiss coronary stent developer Qvanteq AG closes series B financing round of 4 million Swiss Francs to obtain clinical proof of concept and CE mark

Series B financing round Qvanteq AG today announced the successful completion of its series B financing round of 4 million Swiss Francs which has been raised from private investors. The funds will be used to obtain clinical proof of concept in a “First-in-Man” study as well as CE market approval for Qvanteq’s own novel coronary […]